BridgeBio Pharma
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 weeks.
- Recent price momentum is +4.7% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 10.7% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 95.8% | Better than 98% |
| Operating margin | -100.0% | Better than 7% |
| Net margin | -144.4% | Better than 6% |
| Return on equity | -192.4% | Better than 3% |
| Return on invested capital | -78.6% | Better than 3% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -6.7% | Better than 58% |
| 6-month return | 10.0% | Better than 72% |
| 12-month return (ex latest month) | 0.0% | Better than 33% |
| Distance below 52-week high | 18.6% | Better than 63% |
Financial Health D
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.8x | Better than 70% |
| Debt to assets | 199.0% | Better than 0% |
| Interest coverage | -3.1x | Better than 18% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 94.4% | Better than 77% |
| Upside to average target | 44.3% | Better than 62% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 78.18
- Open
- 77.85
- Day range
- 75.46 - 78.24
- Avg price
- 76.44
- Volume
- 1.48M
- Turnover
- 113.03M
- Turnover ratei
- 0.91%
- Volume ratioi
- 0.67
- Amplitudei
- 3.56%
- 52-week rangei
- 62.50 - 93.42
Valuation
- P/Ei
- -20.11
- P/E (TTM)i
- -25.09
- P/Bi
- -5.69
- EPSi
- -3.78
- Book value / shi
- -13.37
- Net profit
- -736.35M
- Net assets
- -2.60B
Share structure
- Market cap
- 14.81B
- Float capi
- 12.39B
- Shares out
- 194.80M
- Float sharesi
- 163.01M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2019-06-27
18.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+104.47M net over the window
Short interest
- Shares short
- 20.85M
- % of floati
- 10.70%
- Days to coveri
- 7.06
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of BridgeBio Pharma (BBIO)?
BridgeBio Pharma last traded at 76.03. This page shows a periodic quote snapshot. Check the displayed quote time.
What is BridgeBio Pharma's market cap?
About 14.81B.
What is the P/E ratio of BridgeBio Pharma?
The trailing twelve-month P/E is -25.09. The Valuation tab shows it against the stock's own five-year range.
Does BridgeBio Pharma pay a dividend?
BridgeBio Pharma does not currently pay a regular dividend.
Is BridgeBio Pharma a buy according to analysts?
The consensus of 18 analysts is a Buy rating, with an average 12-month price target of 109.69, which implies 44.3% upside from the current price. This is not investment advice.
What is BridgeBio Pharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates BridgeBio Pharma a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:01:24 · For reference only, not investment advice and not tailored to your situation.
BridgeBio Pharma discussion 0 comments